一种癌症药物Luucovorin尽管证据不足,但被广泛用作自闭症的非标签用途,造成短缺和安全关切。 A cancer drug, leucovorin, is being widely used off-label for autism despite weak evidence, causing shortages and safety concerns.

一种癌症药物Luucovorin在被与Trump行政当局有关的数字认可为治疗自闭症儿童的一种可能办法后,自闭症社区内的受欢迎程度上升。 A cancer drug, leucovorin, has seen a surge in popularity within the autism community after being endorsed by figures linked to the Trump administration as a potential treatment for autistic children. 尽管用于自闭症的科学证据有限,但需求急剧上升,导致供应短缺。 Despite limited scientific evidence supporting its use for autism, demand has risen sharply, leading to supply shortages. 医学专家警告该药物的非标签自闭症使用缺乏有力的临床支持,并警告其日益受欢迎程度可能超过研究,引起对安全和功效的担忧。 Medical experts caution that the drug’s off-label use for autism lacks robust clinical backing and warn that its growing popularity may outpace research, raising concerns about safety and efficacy. 虽然一些家庭报告说取得了积极成果,但保健专业人员强调,在广泛采用之前必须进行严格的研究。 While some families report positive outcomes, health professionals emphasize the need for rigorous studies before widespread adoption.